Biogenetic glucagon: new preparation.  Four times more expensive for the same service.
(1) Human biogenetic glucagon has replaced traditional glucagon of animal origin.  It is the same substance but is obtained through a different manufacturing process. (2) The file on the efficacy and safety of biogenetic glucagon is limited.  It suggests nevertheless that the hyperglycaemic effect of biogenetic glucagon is equivalent to that of animal glucagon and that the underlying biotechnology does not introduce new risks. (3) The main indication for glucagon is in the treatment of severe hypoglycaemia in insulin-treated diabetic patients.  In this indication glucagon is usually administered by persons with no medical training (relatives) who must be taught when and how to use the drug appropriately. (4) Glucagon has been used for more than 25 years in the treatment of acute betablocker intoxication. Despite the absence of randomised trials most authors consider it superior to beta-adrenergic agonists in severe cases.
D000319:Adrenergic beta-Antagonists / Q000633:toxicity; D000818:Animals; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D016527:Drug Costs; D005934:Glucagon / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D005934:Glucagon